79P Prospective study of endocrine effects and quality of life in paediatric and young CML patients on tyrosine kinase inhibitors: An experience from a tertiary care centre in India

Chronic myeloid leukaemia (CML) is a rare form of childhood cancer, accounting for just 2-3% of paediatric leukaemia’s. While the introduction of tyrosine kinase inhibitors (TKIs) has significantly improved treatment outcomes, their long-term impact on endocrine functions and quality of life (QoL) in children is still not fully understood. This study investigates the off-target effects of TKIs on growth, bone health, metabolism, and QoL in paediatric CML patients.